TomoTherapy posts losses for Q4, FY09

TomoTherapy, a producer of advanced radiation therapy products, has reported a net loss of $3.4 million for the fourth quarter of 2009, as well as $37.4 million loss for the fiscal year ending December 31, 2008.

While the quarterly figure represented an improvement over the $7.5 million loss reported in the year ago quarter, the company reported its net loss for the year was slightly more than the $33.5 million posted in fiscal 2008.

Fourth quarter revenue was $58 million, a drop of 33 percent from the $86.3 million reported in the fourth quarter in 2008. Total revenue for the year was $164 million, a 20 percent decrease from the 12-month period that ended Dec. 31, 2008.

"While we are starting to see some improvement in the 2010 market, especially given lower-than-expected Centers for Medicare & Medicaid Services reductions to reimbursement rates, said Fred Robertson, TomoTherapy’s CEO. “We are still facing a tough competitive environment and a long sales cycle. Therefore, we expect our 2010 revenue and net loss to be comparable to 2009.”

Michael Bassett,

Contributor

Around the web

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.